-
Mashup Score: 2
Speaker- Amer Zeidan Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of CME at Hematology division at Yale Cancer Center. Dr. Zeidan has completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML). The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers di
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
Speaker- Amer Zeidan Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of CME at Hematology division at Yale Cancer Center. Dr. Zeidan has completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML). The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers di
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: 📢Happening TODAY at 5 PM CET Most Important MDS Studies from #ASH24 FREE registration https://t.co/otuOPCnkjH @Dr_AmerZeida…
-
-
Mashup Score: 6Maat pharma : Grâce à ses avancées dans la maladie aiguë du greffon contre l'hôte, MaaT Pharma bondit en Bourse - 7 day(s) ago
(BFM Bourse) – La biotech lyonnaise a annoncé des résultats positifs concernant MaaT013, son candidat-médicament le plus avancé contre la maladie aiguë du …
Source: www.tradingsat.comCategories: General Medicine News, Hem/OncsTweet-
RT @bfmbusiness: Grâce à ses avancées dans la maladie aiguë du greffon contre l'hôte, MaaT Pharma bondit en Bourse https://t.co/9NrOW2AByb…
-
-
Mashup Score: 2
When Anne Maldzinski underwent a blood stem-cell transplant to cure her cancer, the procedure triggered a life-threatening immune reaction that ravaged her intestines, leaving her survival dependent on a surprising treatment: human feces.
Source: www.bloomberg.comCategories: General Medicine News, Hem/OncsTweet-
RT @jwgale: Free gift link⬇️ 6/6 https://t.co/UF87UxjLgu
-
-
Mashup Score: 3
Speaker: Florent Malard Florent Malard is Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University. Florent Malard was a visiting investigator at the Memorial Sloan Kettering Cancer Center in New-York, USA from 2015-2016. He is now a researcher at the Saint-Antoine research Center in Paris and his research focus on Graft-versus-Host disease, microbiota and immunological complication of cellular therapies He is Secretary of the Cellular Therapy and Immunotherapy Working Party of The EBMT. He is associate editor of Bone Marrow Transplantation. He has published more than 100 papers in peer-reviewed journals.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: 📢Join us TODAY AT 6PM CET GVHD: Highlights from #ASH24 Register for FREE https://t.co/CbseEhmdO9 @Florent_Malard @Mohty_EB…
-
-
Mashup Score: 3
Exclusive IACH Webinar Join Dr. Mohamad Mohty, as he delivers an in-depth summary of the most groundbreaking findings in multiple myeloma presented at the ASH 2024 meeting in San Diego. Discover the cutting-edge advancements that will shape the future of myeloma treatment and clinical practice. This is your chance to gain firsthand insights into the latest research breakthroughs from the world’s largest hematology conference. Register now to secure your spot!
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: LIVE Now! 🩸Multiple Myeloma: Highlights from #ASH24 🔗 Register for FREE: https://t.co/avpmHcwsGe @Mohty_EBMT https://t.co/E…
-
-
Mashup Score: 4
Speaker: Josep-Maria Ribera Josep Ribera is a senior consultant of the Clinical Hematology Department and the Stem Cell Transplantation Unit at the Catalan Institute of Oncology, University Hospital ‘Germans Trias i Pujol’ in Badalona, Barcelona, Spain. He is also a Professor of Medicine and Haematology at the Autonomous University of Barcelona, Barcelona, Spain. After gaining his medical degree, Professor Ribera specialised in haematology at the Hospital Clínic de Barcelona, before completing his PhD in the Department of Clinical Hematology. His main areas of scientific interest include acute lymphoblastic leukaemia (ALL) and lymphomas arising in HIV-infected patients. President of the Spanish cooperative Malignant Hemopathies Study and Treatment Program (PETHEMA) Foundation and Chairman of the PETHEMA adult ALL programme, Professor Ribera is also a member of the steering committee of the European LeukemiaNet and the European Working Group for Adult ALL (EWALL). A reviewer for many ha
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: LIVE Now! 📌 MRD in Acute Lymphoblastic Leukemia: Where Do We Stand? 🔗 Register for FREE: https://t.co/j2zhH57kUL @Mohty_EBM…
-
-
Mashup Score: 4
The IACH is thrilled to invite you to join us on an enlightening journey through the evolution of hematology. In this exclusive webinar series, we will explore the transformative discoveries and innovations that continue to impact the diagnosis, treatment, and understanding of blood disorders. Each session will feature in-depth discussions led by a renowned expert, showcasing the scientific milestones, personal stories, and lasting legacies of these trailblazers. This series promises to enrich our knowledge and inspire new perspectives. Speaker: Thierry Facon Thierry Facon, MD, is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. He currently serves as President of the French Society of Hematology (2021-2025) and is a Member of the French Academy of Medicine (Académie Nationale de Médecine). Professor Facon was President of the IFM from 2003 to 2006 and has presented at many international congresses.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: 📢 Don’t miss it! Join us TOMORROW Pioneers in Hematology🩺🩸 ⏲️6pm CET 🔗Register for FREE https://t.co/71Hj6Gn3wg @Mohty_EBMT
-
-
Mashup Score: 4
The IACH is thrilled to invite you to join us on an enlightening journey through the evolution of hematology. In this exclusive webinar series, we will explore the transformative discoveries and innovations that continue to impact the diagnosis, treatment, and understanding of blood disorders. Each session will feature in-depth discussions led by a renowned expert, showcasing the scientific milestones, personal stories, and lasting legacies of these trailblazers. This series promises to enrich our knowledge and inspire new perspectives. Speaker: Thierry Facon Thierry Facon, MD, is Professor of Haematology in the Department of Haematology, Lille University Hospital, Lille, France, a position he has held since 2000. He currently serves as President of the French Society of Hematology (2021-2025) and is a Member of the French Academy of Medicine (Académie Nationale de Médecine). Professor Facon was President of the IFM from 2003 to 2006 and has presented at many international congresses.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: 📢 Don’t miss it! Join us TOMORROW Pioneers in Hematology🩺🩸 ⏲️6pm CET 🔗Register for FREE https://t.co/71Hj6Gn3wg @Mohty_EBMT
-
-
Mashup Score: 35
Exclusive IACH Webinar Join Dr. Mohamad Mohty, as he delivers an in-depth summary of the most groundbreaking findings in multiple myeloma presented at the ASH 2024 meeting in San Diego. Discover the cutting-edge advancements that will shape the future of myeloma treatment and clinical practice. This is your chance to gain firsthand insights into the latest research breakthroughs from the world’s largest hematology conference. Register now to secure your spot!
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
Get ready for an exciting week ahead as @TheIACH leads the way in hematology education with 3 major webinars that will keep us at the forefront of the field-don't miss out! https://t.co/71AzpI51HF @COMyCongress @TheEBMT_Nurses https://t.co/fe6QcijUKQ https://t.co/ahmNqqnqQK
-
RT @TheIACH: 📢Happening TODAY at 5 PM CET Most Important MDS Studies from #ASH24 FREE registration https://t.co/otuOPCnkjH @Dr_AmerZeida…